GW572016 For Treatment Of Refractory Metastatic Breast Cancer

Mise à jour : Il y a 4 ans
Référence : NCT00062686

Femme Homme

Extrait

This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.


Critère d'inclusion

  • Neoplasms, Breast


Liens